NautaDutilh assisted Sanofi with its public offer for Kiadis Pharma.
Sanofi, a global leader in healthcare, and Kiadis Pharma N.V., a Dutch biotechnologist listed on Euronext Amsterdam and Brussel, announced their agreement on a recommended public offer for all outstanding Kiadis shares at an offer price of EUR 5.45, valuing the company at approximately EUR 308 million. The offer price represents an extraordinary premium of 272% over the closing price of Kiadis’ shares as of 30 October 2020.
Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf’ NK-cells from a healthy donor. NK-cells seek and identify malignant cancer cells and have broad application across various tumor types. The platform has the potential to make products rapidly and economically available for a broad patient population across a wide range of indications. Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.
The team was led by Leo Groothuis (Picture) and further consisted of: Ruud Smits, Philippe Remels, Sybren de Beurs, Jos Somers, Eva van Rooijen, Dineth de Graaf, Mariska Ramdhani-Kamta and Thomas Castermans (Corporate M&A), David Viëtor and Linda Tomassen (Finance), Nina Kielman (Tax), Paul van der Bijl and Koen Biesma (Corporate notarial) and Jeroen Boelens (IP/Pharma).
Involved fees earner: Koen Biesma – NautaDutilh; Jeroen Boelens – NautaDutilh; Thomas Castermans – NautaDutilh; Sybren de Beurs – NautaDutilh; Dineth de Graaf – NautaDutilh; Leo Groothuis – NautaDutilh; Nina Kielman – NautaDutilh; Mariska Ramdhani-Kamta – NautaDutilh; Philippe Remels – NautaDutilh; Ruud Smits – NautaDutilh; Jos Somers – NautaDutilh; Linda Tomassen – NautaDutilh; Paul van der Bijl – NautaDutilh; Eva van Rooijen – NautaDutilh; David Viëtor – NautaDutilh;
Law Firms: NautaDutilh;
Clients: Sanofi S.A.;